Sialorrhea is often treated with anticholinergic agents, but they can have undesirable side effects such as drowsiness, sedation, and constipation. Effective medication that acts selectively on the salivary glands is needed.
Introduction
Sialorrhea, also called hypersalivation, is characterized by an increased amount of saliva in the mouth. In the case of production sialorrhea (true sialorrhea), this is due to the hypersecretion of saliva, whereas in retention sialorrhea (false sialorrhea), the cause is the failure of the mechanisms that clear and remove saliva from the oral cavity. In patients with a normal salivary flow rate, the sialorrhea may be psychogenic.
Sialorrhea is treated medically with anticholinergic agents such as first-generation antihistamines, tricyclic antidepressants, and anticonvulsants. However, these medicines can cause undesirable side effects such as drowsiness, sedation, and constipation. There is a need for effective medication that shows higher selectivity for the salivary glands.
Here, we report a case of production sialorrhea successfully treated by the combined use of selective M1 and M3 muscarinic receptor antagonists. 99m TcO 4− scintigraphy was useful for diagnosis, revealing the characteristic increased salivary excretion rate.
Case Presentation
A 51-year-old man was referred to our department with a 2-year history of sialorrhea. His medical history was unremarkable except for an allergy to cedar pollen and insomnia, and he was prescribed haloperidol for 10 days each month. He reported that his saliva was mucoid and that it was secreted spontaneously during the day but did not disturb him during sleep at night. Two months after the onset of sialorrhea, he experienced abdominal pain, diarrhea, and constipation. He was diagnosed with and both submandibular glands were drawn on the sequential images and a time-activity curve (TAC) was generated for each region.
A normal TAC ( Fig. 1) showed an early fast-rising component, representing the vascular perfusion of the radiotracer into the gland, followed by a slow-rising component associated with the accumulation of the ra- For the present patient, the TAC images showed an apparently normal fast-rising component, but the following component declined slowly instead of the normal slow rise; this was due to excretion of the radiotracer into the oral cavity ( Fig. 2A) . Tmax was 7 min for both parotid glands and 4 min for both submandibular glands ( Fig. 2   B) ; these time points were arrived at earlier than normal.
The washout rates for the parotid glands were somewhat below the normal range (right, 40%; left 46%), and those for the submandibular glands were moderately decreased (right, 25%; left, 22%). These decreases were interpreted In summary, the patient's scintigraphic results showed spontaneous saliva secretion without stimulation, which indicated that the patient had production type sialorrhea.
Management and Outcome
The patient refused first-generation antihistamines and tricyclic antidepressants out of concern they would cause drowsiness. Therefore, from week 3 to 39 after the first visit, various medicines were administered: ninzintô (considered the first choice for sialorrhea among Kampo medicines), Scopolia extract (a nonspecific anticholinergic agent), tofisopam (an anxiolytic), fexofenadine/pseudoephedrine (to treat the pollen allergy), and escitalopram (a selective serotonin reuptake inhibitor). However, neither the salivary flow rate nor the patient's subjective symptoms showed any marked improvement (Fig. 3) . At (Fig. 4) .
Discussion
This case highlighted two important clinical findings. We therefore expect the result for our case would be generalizable to other cases of sialorrhea. 
Conclusion
We reported here a case of production sialorrhea with no underlying disease. 
